

Mirvetuximab soravtansine MIRASOL, Study 0416

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit

Serious and disabling adverse effects



Other adjustments



Mirvetuximab soravtansine MIRASOL, Study 0416

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies
Therapeutic Indication: Mirvetuximab soravtansine for adult patients with FRα positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1-3 prior systemic treatment regimens
Experimental Arm: Mirvetuximab soravtansine
Control Arm: Paclitaxel, pegylated liposomal doxorubicin, or topotecan.
(Investigator's choice of chemotherapy)



